Rebecca Taub, Director at MADRIGAL PHARMACEUTICALS, INC. (MDGL), sold 45,802 shares at $352.64 ($16.2M) on 2025-07-16, disclosed to the SEC on 2025-07-18.
Scheduled sale ($16.2M) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $350.19 | 6,000 | $2.1M | 13.0% |
| 2 | $351.37 | 1,897 | $667K | 4.1% |
| 3 | $351.37 | 1,897 | $667K | 4.1% |
| 4 | $352.64 | 2,357 | $831K | 5.1% |
| 5 | $352.64 | 2,357 | $831K | 5.1% |
| 6 | $353.82 | 2,569 |
| $909K |
| 5.6% |
| 7 | $353.82 | 2,569 | $909K | 5.6% |
| 8 | $354.61 | 5,800 | $2.1M | 12.7% |
| 9 | $355.61 | 6,441 | $2.3M | 14.1% |
| 10 | $355.61 | 6,441 | $2.3M | 14.1% |
| 11 | $356.52 | 1,380 | $492K | 3.0% |
| 12 | $356.52 | 1,380 | $492K | 3.0% |
| 13 | $350.09 | 2,057 | $720K | 4.4% |
| 14 | $350.09 | 2,057 | $720K | 4.4% |
| 15 | $351.50 | 600 | $211K | 1.3% |
| Total | $353.42 avg | 45,802 | $16.2M | 100% |
| Filing → |
| MDGL | SELL | 2026-01-20 | $1.1M | — | Filing → |
| MDGL | SELL | 2026-01-13 | $18.9M | — | Filing → |
| MDGL | SELL | 2026-01-13 | $242K | — | Filing → |